Amphenol Corporation
—- Market cap
- $103.53B
- Debt
- —
- Cash
- −$11.13B
Complete market value, debt and cash evidence is required for enterprise value.
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · Mkt capMarket cap $103.53B · View financials
Snapshot Sep 11, 2026, 12:05 PM ET
FY 2026 · Mkt cap
Decision snapshot: APH stock price near parity vs EXEL $83.97 current versus $67.68 implied using P/E multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at EXEL's multiple
Implied fair value · at APH's multiple
Snapshot Sep 11, 2026, 12:05 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Lower is better
Higher P/E
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Ten period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
AMPHENOL CORPORATION · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Exelixis Inc · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
TE Connectivity plc
APH vs TEL
CORNING INC /NY
APH vs GLW
CommScope Holding Company, Inc.
APH vs COMM
HUBBELL INC
APH vs HUBB
BEL FUSE INC /NJ
APH vs BELFA
VISHAY INTERTECHNOLOGY INC
APH vs VSH
AMGEN INC
APH vs AMGN
BIOGEN INC.
APH vs BIIB
GILEAD SCIENCES, INC.
APH vs GILD
INCYTE CORP
APH vs INCY
Sarepta Therapeutics, Inc.
APH vs SRPT
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe APH can sustain its 51.7% revenue growth and defend its current premium multiples, then hold or only trim modestly because its operating profile is strong; if not, the data support reducing exposure because the implied P/E value of $67.10 and DCF range of $38.21-$51.70 are far below the current price.
APH trades well above EXEL on valuation, with a current price of $164.59 versus an implied P/E price of $67.10, implying -59.2% downside. The gap is broad across P/E, P/S, EV/EBITDA, and EV/Revenue, though APH also has larger scale and faster revenue growth than EXEL.
Supporting Metrics